<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
  <head><style>.sub-copy a:hover{text-decoration:underline !important}@font-face {}@font-face {}@font-face {}@media screen and (max-width: 400px){.narrow--dt{padding-left:0 !important;padding-right:0 !important}.narrow__2--dt{padding-left:20px !important;padding-right:20px !important}}@media (prefers-color-scheme: dark){body{background-color:#f6f9fc !important;color:black !important}center,.webkit{background-color:#ffffff !important}table{color:#4a4a4a !important}.transparent{background-color:transparent !important}}@media only screen and (min-width: 500px){.title-line{height:87px !important}.desired-break{display:block !important}.padding-right{padding-right:55px !important}}@media only screen and (max-width: 700px){.register-cap{display:block !important}}</style>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Fintepla</title>
    

    
  </head>
  <body style="margin: 0; padding: 0">
    <center class="wrapper" style="
        width: 100%;
        table-layout: fixed;
        background-color: #f6f9fc;
        padding-bottom: 40px;
      ">
      <div class="webkit" style="max-width: 600px; background-color: #ffffff">
        <table class="outer" style="
            width: 100%;
            max-width: 600px;
            margin: 0 auto;
            border-spacing: 0;
            font-family: Lato, Arial, sans-serif;
            color: #4a4a4a;
          ">
          
          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="
                      padding: 0;
                      background-color: #682b8d;
                      text-align: center;
                    ">
                    <p class="sub-copy" style="
                        font-size: 12px;
                        line-height: 18px;
                        color: #ffffff;
                        margin-left: auto;
                        margin-right: auto;
                        display: inline-block;
                        text-align: left;
                      ">
                      INTENDED FOR HEALTHCARE PROFESSIONALS IN THE UK ONLY <br />
                      Prescribing information and adverse event reporting can be found
                      <a href="https://www.zogenixresources.eu/UK-Fintepla-fenfluramine-Prescribing-Information.pdf" target="_blank" class="sub-copy" style="
                          font-size: 12px;
                          line-height: 18px;
                          color: #63585c;
                          color: #682b8d;
                          text-decoration: underline;
                          color: #ffffff;
                        ">here</a>
                  </p></td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 30px;
                padding-bottom: 35px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0; vertical-align: top">
                    <img src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/main-logo.png" alt="" width="143" style="border: 0" />
                  </td>
                  <td style="padding: 0; vertical-align: top">
                    <img src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/zogenix_purple_new.png" alt="" width="111" style="border: 0; float: right" />
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow__2--dt" style="padding: 0; padding-left: 40px; padding-right: 40px">
              <table width="100%" style="
                  width: 100%;
                  border-spacing: 0;
                  /* background-color: #f5f2f7; */
                ">
                <tr>
                  <td style="padding: 0">
                    <table style="width: 100%; border-spacing: 0">
                      <tr style="background-color: #f5f2f7">
                        <td class="narrow" style="
                            padding: 0;
                            padding-left: 20px;
                            padding-right: 20px;
                          ">
                          <div class="title-line" style="width:3px;background-color:#d23d56;height:107px"></div>
                        </td>
                        <td style="padding: 0; padding-right: 20px">
                          <p style="font-size: 22px; color: #682b8d; line-height: 1.25;">
                            <span class="desired-break" style="padding-right:0px">NICE PUBLISHES TECHNOLOGY</span>
                            <span class="desired-break" style="padding-right:0px">APPRAISAL GUIDANCE IN</span>
                            <span class="desired-break" style="padding-right:0px">DRAVET SYNDROME</span>
                          </p>
                        </td>
                      </tr>
                    </table>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow--dt" style="padding: 0; padding-left: 20px; padding-right: 20px">
              <img src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/fintepla_banner_image_2.png" alt="Banner" width="600px;" style="border: 0; max-width: 100%" />
            </td>
          </tr>
          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 15px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Dear <span id="mailto-name"></span>,
              </p>
              <p class="copy padding-right" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                We are delighted to inform you that the National Institute for Health and Care Excellence (NICE) has published its technology appraisal guidance (TAG) for Fintepla<img src="https://storage.finervision.com/public/emailers/traingle.png" alt="triangle" />(fenfluramine*) for the treatment of seizures associated with Dravet syndrome.
              </p>
              <p class="copy" style="
                padding-bottom: 5px;
                font-size: 15px;
                line-height: 25px;
                color: #D23D56;
              ">
              In the TAG, NICE recommends fenfluramine as an add-on to other antiepileptic medicines for treating seizures associated with Dravet syndrome in people aged
                2 years and older, only if<sup>1</sup>:
                <br />
                <ul class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #D23D56;
                  padding-right: 40px;
                ">
                  <li><strong><i>seizures have not been controlled after trying 2 or more antiseizure medicines</i>
                  </strong></li>
                  <li><strong><i>the frequency of convulsive seizures is checked every 6 months,
                    and fenfluramine is stopped if it has not fallen by at least 30%
                    compared with the 6 months before starting treatment</i>
                  </strong></li>
                  <li><strong><i>the company provides fenfluramine according to the
                    commercial arrangement.</i>
                  </strong></li>
                </ul>
              </p>
            </td>
          </tr>
          
          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tbody class="transparent" style="background-color:transparent">
                  <tr>
                    <td style="
                        padding: 0;
                        padding-bottom: 15px;
                        text-align: center;
                        vertical-align: middle; ;
                      ">
                      <a href="https://www.nice.org.uk/guidance/gid-ta10373/documents/html-content-3" target="_blank" class="register-btn" style="
                          color: white;
                          background-color: #D23D56;
                          text-decoration: none;
                          font-size: 15px;
                          padding: 12px 32px;
                          border-width: 2px;
                          border-style: solid;
                          border-color: #D23D56;
                        ">View the full TAG here</a>
                    </td>
                  </tr>

                </tbody>
              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 15px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Following the TAG publication on 8th July 2022, the NHS has now entered a 90-day
                implementation phase. This period enables the Trusts included in the Bluteq list
                (who will become prescribing centres) to prepare for when central funding becomes
                available for Fintepla. We anticipate that Day 91 will be <strong>6th October 2022</strong> when
                clinicians will be able to prescribe Fintepla to their patients for the treatment of
                seizures associated with Dravet syndrome, as described in the TAG guidance.
              </p>
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                As part of the approval of Fintepla, there is a requirement for a Risk Management
                Programme (RMP) to ensure that the currently approved indication is strictly
                adhered to, and that physicians are adequately informed of the requirement to
                perform periodic echocardiogram monitoring when prescribing Fintepla.
              </p>
            </td>
          </tr>

          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tbody class="transparent" style="background-color:transparent">
                <tr>
                  <td style="
                        padding: 0;
                        padding-top: 10px;
                        padding-bottom: 15px;
                        text-align: center;
                        vertical-align: middle; ;
                      ">
                    <a href="https://www.nice.org.uk/guidance/gid-ta10373/documents/html-content-3" target="_blank" class="register-btn" style="
                          color: white;
                          background-color: #682B8D;
                          text-decoration: none;
                          font-size: 15px;
                          padding: 12px 32px;
                          border-width: 2px;
                          border-style: solid;
                          border-color: #682B8D;
                        ">View the RMP guidance here</a>
                  </td>
                </tr>

                </tbody>
              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 15px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                To support the RMP, a Controlled Access Programme (CAP) is now available,
                providing a central source for the key information around prescribing Fintepla.
                Registration in the CAP programme will generate a Prescriber ID number.
                <strong>All physicians will need a Prescriber ID number before they can write
                  prescriptions for Fintepla.</strong>
              </p>
            </td>
          </tr>

          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0">
                <tbody class="transparent" style="background-color:transparent">
                <tr>
                  <td style="
                        padding: 0;
                        padding-bottom: 15px;
                        text-align: center;
                        vertical-align: middle; ;
                      ">
                    <a href="https://www.nice.org.uk/guidance/gid-ta10373/documents/html-content-3" target="_blank" class="register-cap" style="
                          color: white;
                          display: inline-block;
                          background-color: #D23D56;
                          text-decoration: none;
                          font-size: 15px;
                          padding: 12px 32px;
                          margin: 0 12px;
                          border-width: 2px;
                          border-style: solid;
                          border-color: #D23D56;
                        ">Click here to register for the CAP programme, and receive a Prescriber ID</a>
                  </td>
                </tr>

                </tbody>
              </table>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Registration takes approximately 6 minutes.<br />
                Step 1 &#x2013; complete personal details<br />
                Step 2 &#x2013; verify identity via email or SMS<br />
                Step 3 &#x2013; read the page of information<br />
                Step 4 &#x2013; attest that the information has been read and understood<br />
                Step 5 &#x2013; receive Prescriber ID<br />
              </p>
            </td>
          </tr>

          
          <tr>
            <td style="padding: 0">
              <table style="width: 100%; border-spacing: 0;table-layout: fixed">
                <tr style="
                      padding: 0;
                      vertical-align: middle;
                      background-color: #682b8d; 
                    ">
                  <td colspan="2">
                    <p style="font-size:15px;font-weight:300;color:#ffffff;padding:0 40px;line-height:1.5;">
                      You are invited to attend one of the launch meetings to be held in:
                    </p>
                  </td>
                </tr>
                <tr style="
                padding: 0;
                text-align: center;
                vertical-align: middle;
                background-color: #682b8d; 
              ">
                  <td style="font-weight:bold;font-size:16px;color:#ffffff;padding:0 40px;line-height:1.5;">
                    <p style="margin: 0;">Manchester: Malmaison Hotel,</p>
                    <p style="margin: 0;">Wednesday 28th September,</p>
                    <p style="margin: 0;">7-9pm</p>
                  </td>
                  <td style="font-weight:bold;font-size:16px;color:#ffffff;padding:0 40px;line-height:1.5;">
                    <p style="margin: 0;">London: Park Plaza Hotel,</p>
                    <p style="margin: 0;">Thursday 29th September,</p>
                    <p style="margin: 0;">7-9pm</p>
                  </td>
                </tr>
                <tr style="
                      padding: 0;
                      vertical-align: middle;
                      background-color: #682b8d; 
                    ">
                  <td colspan="2">
                    <p style="font-size:15px;font-weight:300;color:#ffffff;padding:0 40px;line-height:1.5;">
                    Both will be hybrid meetings, enabling online and in-person attendance
                    </p>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="padding: 0; background-color: #f5f2f7">
                    <p style="padding-left: 20px;color: #682b8d;">
                      <strong>Topics will include:</strong>
                    </p>
                    <ul style="
                        padding-bottom: 5px;
                        padding-left: 40px;
                        padding-right: 40px;
                      ">
                      <li style="
                          font-size: 15px;
                          line-height: 25px;
                          color: #682b8d;
                        ">
                        <p style="margin-bottom: 5px; padding-left: 20px">
                          An update on what the NICE TAG guidance means for the use of Fintepla to treat patients with Dravet syndrome
                        </p>
                      </li>
                      <li style="
                          font-size: 15px;
                          line-height: 25px;
                          color: #682b8d;
                        ">
                        <p style="
                            margin-bottom: 5px;
                            margin-top: 0;
                            padding-left: 20px;
                          ">
                          Current diagnosis and treatment landscapes for Dravet
                          syndrome
                        </p>
                      </li>
                      <li style="
                          font-size: 15px;
                          line-height: 25px;
                          color: #682b8d;
                        ">
                        <p style="
                            margin-bottom: 5px;
                            margin-top: 0;
                            padding-left: 20px;
                          ">
                          Exploring what additional treatment options mean for people with
                          Dravet syndrome and their families
                        </p>
                      </li>
                      <li style="
                          font-size: 15px;
                          line-height: 25px;
                          color: #682b8d;
                        ">
                        <p style="
                            margin-bottom: 5px;
                            margin-top: 0;
                            padding-left: 20px;
                          ">
                          Fintepla clinical trial data and Real World Evidence
                        </p>
                      </li>
                    </ul>
                  </td>
                </tr>
                <tr>
                  <td colspan="2" style="
                      padding: 0;
                      padding-top: 10px;
                      padding-bottom: 30px;
                      text-align: center;
                      vertical-align: middle;
                      background-color: #f5f2f7" "="">
                    <a href="https://zogenix.wavecast.io/fintepla-2022/registration?utm_source=Digital&amp;utm_medium=Email&amp;utm_campaign=Register_interest" target="_blank" class="register-cap" style="
                        color: white;
                                                  display: inline-block;
                        background-color: #D23D56;
                        text-decoration: none;
                        font-size: 15px;
                        font-weight: bold;
                        margin: 0 12px;
                        padding: 15px 40px;
                        border-width: 2px;
                        border-style: solid;
                        border-color: #D23D56;
                      ">Click here to register for either the London or Manchester meetings </a>
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
              <td colspan="2" style="padding:0.5rem;"></td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 12px;
                  color: #66575c;
                ">
                *Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on
                therapy to other antiepileptic medicines for patients 2 years of age and older.<sup>2</sup>
              </p>
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #66575c;
                  text-align: right;
                ">
                These promotional meetings are funded and organised by Zogenix, a part of UCB.
              </p>
            </td>
          </tr>


          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  padding-bottom: 5px;
                  font-size: 15px;
                  line-height: 25px;
                  color: #66575c;
                ">
                Kind regards<br />
                Rep&apos;s Full Name<br />
                Rep&apos;s Title<br />
                Email address And Phone number<br />
              </p>
            </td>
          </tr>


          <tr>
            <td class="narrow" style="
                padding-right: 20px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0; text-align: center">
                    <img width="136" src="https://evrenzo.s3.eu-west-2.amazonaws.com/fintepla/zogenix_purple_new.png" alt="Zogenix Logo" style="border: 0" />
                  </td>
                </tr>
              </table>
            </td>
          </tr>
          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-top: 20px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0">
                    <p class="sub-copy" style="font-size: 12px; line-height: 18px; color: #63585c">
                      For any medical questions, please email
                      <a href="mailto:medinfo.eu@zogenix.com" style="color: #682b8d; text-decoration: none">medinfo.eu@zogenix.com</a>
                    </p>
                  </td>
                </tr>
                <tr>
                  <td style="padding: 0">
                    <p style="
                        font-size: 12px;
                        font-weight: bold;
                        color: #682b8d;
                        line-height: 15px;
                      ">
                      References:
                    </p>
                    <ol style="
                        padding-right: 20px;
                        padding-top: 0;
                        padding-left: 16px;
                        font-size: 12px;
                      ">
                      <li style="padding-left: 24px; line-height: 12px">
                        <p style="line-height: 12px">
                          NICE. Fenfluramine Technology appraisal guidance. Available at: https://www.nice.org.uk/guidance/TA808.
                          Accessed August 2022.
                        </p>
                      </li>
                      <li style="padding-left: 24px; line-height: 12px">
                        <p style="line-height: 12px">Fintepla Summary of Product Characteristics.
                        </p>
                      </li>
                    </ol>
                  </td>
                </tr>
              </table>
            </td>
          </tr>


          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
              ">
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #66575c;
                ">
                The information in this email is confidential, is intended for the addressed recipient only and must not
                be copied, distributed or disclosed. Any subsequent action taken with this email, including forwarding is not
                the responsibility of UCB or its affiliates. If you are not the intended recipient of this email, you are hereby
                notified that any disclosure, copying, distribution or taking action in relation of the contents of this email is
                strictly prohibited and may be unlawful.
              </p>
            </td>
          </tr>

          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 15px;
              ">
              <p class="copy" style="
                  font-size: 12px;
                  line-height: 25px;
                  color: #66575c;
                ">
                This email is sent to <u>NN.NN@com.com</u> because you indicated that you are willing to receive occasional
                emails based on your preferences. If you do not wish to receive such emails in the future please send an
                email to <a style="color: #63585c" href="mailto:neurology.solutions@ucb.com">neurology.solutions@ucb.com</a> with UNSUBSCRIBE in the subject line.
              </p>
            </td>
          </tr>



          
          <tr>
            <td class="narrow" style="
                padding: 0;
                padding-left: 20px;
                padding-right: 20px;
                padding-bottom: 10px;
              ">
              <table style="width: 100%; border-spacing: 0">
                <tr>
                  <td style="padding: 0; vertical-align: top; float: left; width: 33.33%;">
                    <a href="https://www.zogenixresources.eu/Zogenix-Privacy-Policy-Master.pdf" target="_blank" style="color: #63585c"><p class="sub-copy" style="font-size: 12px; line-height: 18px; ">Privacy policy</p></a>
                  </td>

                  <td style="padding: 0; vertical-align: top; float: left; width: 33.33%;">
                    <p class="sub-copy" style="font-size: 12px; line-height: 18px; color: #63585c; text-align: center">
                      GB-P-FA-DS-2200021
                    </p>
                  </td>

                  <td style="padding: 0; vertical-align: top; float: left; width: 33.33%;">
                    <p class="sub-copy" style="font-size: 12px; line-height: 18px; color: #63585c; text-align: right">
                      August 2022
                    </p>
                  </td>

                </tr>
              </table>
            </td>
          </tr>

          
          <tr>
            <td class="narrow" style="padding: 0; padding-left: 20px; padding-right: 20px">
              <p class="sub-copy footer-box" style="
                  font-size: 12px;
                  line-height: 18px;
                  color: #63585c;
                  max-width: 560px;
                  border-width: 1px;
                  border-style: solid;
                  border-color: #63585c;
                  padding-top: 20px;
                  padding-bottom: 20px;
                  padding-right: 43px;
                  padding-left: 43px;
                  text-align: center;
                ">
                Adverse events should be reported. Reporting forms and
                information can be found at
                <a href="https://yellowcard.mhra.gov.uk/" target="_blank" style="color: #682b8d; text-decoration: none">https://yellowcard.mhra.gov.uk/</a>
                or search for MHRA Yellow Card in the Google Play or Apple App
                Store. Adverse events should also be reported to Zogenix
                International Limited on
                <a href="tel:+448000608767" style="color: #682b8d; text-decoration: none">0800 060 8767</a>
                or email
                <a href="mailto:medinfo.eu@zogenix.com" style="color: #682b8d; text-decoration: none">medinfo.eu@zogenix.com</a>.
              </p>
            </td>
          </tr>
        </table>
      </div>
    </center>
  </body>
</html>
